Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections (CROI) Boston, Massachusetts March 4-7, 2018 Back

Bictegravir at CROI       CROI: Switch to Bictegravir/F/TAF From DTG and ABC/3TC - (03/05/18)   CROI: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Women - (03/06/18)   CROI: Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results - (03/06/18)   CROI: Pharmacokinetics of Bictegravir Administered Twice Daily In Combination With Rifampin - (03/06/18)   CROI: Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy®(Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine - (03/05/18)